Edition:
United Kingdom

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Global Market

7.86USD
17 Sep 2018
Change (% chg)

-- (--)
Prev Close
$7.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
49,512
52-wk High
$11.47
52-wk Low
$4.30

Select another date:

Mon, Jul 30 2018

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

RedHill BioPharma has positive results from Crohn's disease trial

TEL AVIV, July 30 Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share

* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia

* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION

BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg

* PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:

BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis

* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING

Select another date: